Ipilimumab

Where the papers sit

17 papers from the last 6 months study ipilimumab directly · updated from PubMed 12 Oct 2026

• Dual Checkpoint Immunotherapy

  Dual checkpoint blockade with nivolumab plus ipilimumab is being tested across NSCLC, hepatocellular, biliary and neuroendocrine cancers, including PD-L1-low disease. Objective response and progression-free survival recur as endpoints, with anti-PD-L1 combinations and triplets challenging single strategies. Early detriment signals and variable benefit keep tumour-agnostic reimbursement and patient selection unresolved. The shared aim is to overcome PD-(L)1 resistance while preserving durable complete responses.

  10 papers · 58.8%

• Renal Cancer Treatment Outcomes

  First-line nivolumab plus ipilimumab is being judged against standard care in advanced renal cell carcinoma, with clinical scores and cost-effectiveness shaping selection. Papillary RCC remains less certain than clear-cell disease, while real-world esophageal squamous-cell data broaden the combination’s clinical scope. Outcomes and value vary across China and US models, leaving optimal eligibility and sequencing open. The work favors evidence-guided use rather than assuming combination therapy is universally worthwhile.

  4 papers · 23.5%

• Immunotherapy Resistance in Cancer

  Checkpoint immunotherapy is being examined through melanoma plasticity, brain metastasis outcomes and combination treatment of GIST. NRAS status, treatment discontinuation and entinostat or imatinib recur as possible modifiers of response. The studies do not establish one shared therapeutic direction, but they converge on resistance, tumour-state change and the limits of durable benefit. Clinical melanoma data sit alongside mechanistic and early combination evidence.

  3 papers · 17.6%